Anti-SARS-CoV-2 Nucleoprotein Monoclonal antibody (CABT-CS051)

Mouse Anti-SARS-CoV-2 Nucleoprotein Monoclonal antibody for ELISA

Specifications


Host Species
Human
Antibody Isotype
IgG
Clone
TMOPO
Species Reactivity
SARS-CoV-2
Conjugate
unconjugated

Data Examples


12% SDS-PAGE analysis profiles of purified CABT-CS051
Lane M: Protein Marker
Lane 1: CABT-CS051,Non-Reducing (2ug)
Lane 2: CABT-CS051,Reducing (2ug)

Target


Alternative Names
SARS-CoV-2; coronavirus; SARS-CoV-2 NP; SARS-CoV-2 Nucleocapsid Protein; 2019 Novel Coronavirus

Citations


Have you cited CABT-CS051 in a publication? Let us know and earn a reward for your research.

Custom Antibody Labeling


We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody. Learn More

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Nanotechnology Responses to COVID-19

ADVANCED HEALTHCARE MATERIALS

Authors: Ruiz-Hitzky, Eduardo; Darder, Margarita; Wicklein, Bernd; Ruiz-Garcia, Cristina; Martin-Sampedro, Raquel; del Real, Gustavo; Aranda, Pilar

Researchers, engineers, and medical doctors are made aware of the severity of the COVID-19 infection and act quickly against the coronavirus SARS-CoV-2 using a large variety of tools. In this review, a panoply of nanoscience and nanotechnology approaches show how these disciplines can help the medical, technical, and scientific communities to fight the pandemic, highlighting the development of nanomaterials for detection, sanitation, therapies, and vaccines. SARS-CoV-2, which can be regarded as a functional core-shell nanoparticle (NP), can interact with diverse materials in its vicinity and remains attached for variable times while preserving its bioactivity. These studies are critical for the appropriate use of controlled disinfection systems. Other nanotechnological approaches are also decisive for the development of improved novel testing and diagnosis kits of coronavirus that are urgently required. Therapeutics are based on nanotechnology strategies as well and focus on antiviral drug design and on new nanoarchitectured vaccines. A brief overview on patented work is presented that emphasizes nanotechnology applied to coronaviruses. Finally, some comments are made on patents of the initial technological responses to COVID-19 that have already been put in practice.

Persistence ofSARS-CoV-2 nasopharyngeal swabPCRpositivity inCOVID-19 convalescent plasma donors

TRANSFUSION

Authors: Ikegami, Sachie; Benirschke, Robert; Flanagan, Tara; Tanna, Nicole; Klein, Tovah; Elue, Rita; Debosz, Patricia; Mallek, Jessica; Wright, Gregory; Guariglia, Perry; Kang, Jason; Gniadek, Thomas J.

Background Nucleic acid persists after symptom resolution and infectivity for many viral infections via delayed clearance of nucleic acid fragments, non-infectious particles, or transmissible virus. For Coronavirus Disease 2019 (COVID-19), the relationship between nasopharyngeal (NP) swab positivity, the development of antibodies against COVID-19, and clinical history are unclear. Study design and methods Individuals who recovered from COVID-19 and volunteered to donate convalescent plasma (CP) were screened by NP swab PCR, responded to a questionnaire, and were tested for anti-COVID-19 antibodies. Results A proportion of 11.8% of individuals tested positive for SARS-CoV-2 by NP swab PCR greater than 14 days after the resolution of symptoms of active disease, including one donor who had asymptomatic disease and tested positive by NP swab 41 days after her initial diagnosis. Clinical history did not show a significant correlation with persistence of NP swab positivity. Also, NP swab positivity >14 days from symptom resolution did not correlate with anti-COVID-19 serology results. IgG anti-SARS-CoV-2 spike antibody strength correlated with hospitalization for COVID-19 using two different assays. Total anti-SARS-CoV-2 nucleocapsid antibody strength correlated with time from symptom resolution to sample collection and symptom duration. Conclusions SARS-CoV-2 nucleic acid is detectable long after the resolution of symptoms in a significant percentage of previously diagnosed individuals, which is important to consider when interpreting PCR swab results. Persistence of PCR positivity does not correlate with antibody strength or symptoms of COVID-19. If anti-spike antibody is used to assess CP potency, individuals who suffered severe COVID-19 disease symptoms may represent better donors.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket